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Abstract
Von Hippel-Lindau disease (VHL) is a rare autosomal dominant disease characterized by
development of cystic and tumorous lesions at multiple sites, including the brain, spinal cord,
kidneys, adrenals, pancreas, epididymis and eyes. The clinical phenotype results from molecular
abnormalities of the VHL tumor suppressor gene, mapped to human chromosome 3p25-26. The
VHL gene encodes two functionally active VHL proteins due to the presence of two translational
initiation sites separated by 53 codons. The majority of disease-causing mutations have been
detected downstream of the second translational initiation site, but there are conflicting data as to
whether few mutations located in the first 53 codons, such as the Pro25Leu could have a
pathogenic role. In this paper we report a large Hungarian VHL type 2 family consisting of 32
members in whom a disease-causing AGT80AAT (Ser80Ile) c.239G>A, p.Ser80Ile mutation, but
not the concurrent CCT25CTT (Pro25Leu) c.74C>T, p.Pro25Leu variant co-segregated with the
disease. To our knowledge, the Ser80Ile mutation has not been previously described in VHL type
2 patients with high risk of pheochromocytoma and renal cell cancer. Therefore, this finding
represents a novel genotype-phenotype association and VHL kindreds with Ser80Ile mutation will
require careful surveillance for pheochromocytoma. We concluded that the Pro25Leu variant is a
rare, neutral variant, but the presence such a rare gene variant may make genetic counseling
difficult.
Background
Von Hippel-Lindau disease (VHL) (OMIM nr. 193300) is
a rare autosomal dominant multi-organ disease caused by
molecular abnormalities of the VHL  tumor suppressor
gene [1]. Patients with VHL are at risk for development of
retinal, cerebellar, spinal, pancreatic and renal heman-
gioblastomas, pulmonary and liver hemangiomas, clear-
cell renal carcinomas, pheochromocytomas, endolym-
phatic sac tumors, multiple renal, epididymal and pancre-
atic cysts, cystadenomas of the epididymis and of the
broad ligament, and pancreatic islet cell tumors [1-3].
Based on the presence or absence of pheochromocytoma,
two main subtypes of the VHL disease have been identi-
fied. Patients with VHL type 1 are at risk to develop renal
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cell carcinoma and hemangioblastoma but predomi-
nantly without pheochromocytoma, while those with
VHL type 2 may have all manifestations of the disease pre-
dominantly including pheochromocytoma. VHL type 2
has been subdivided into subtype 2A and 2B, with a low
and high risk of renal cell carcinoma, respectively,
whereas subtype 2C is a pheochromocytoma-only pheno-
type. The prevalence of the VHL disease varies between
1:39,000 in Germany and 1:53,000 in East Anglia [4,5].
Manifestations of the disease show variable expression
and several patients may have only one manifestation [4].
The human VHL gene maps to chromosome 3p25-26 [1].
As predicted by Knudson's two-hit model, tumor develop-
ment requires inactivation of both copies; the first hit, the
germline mutation or deletion is followed by somatic
alterations usually detected as loss of heterozygosity. The
VHL gene has two translational initiation sites separated
by 53 codons. Of the two proteins encoded by the VHL
gene, the larger one contains 213 amino acids (pVHL30),
whereas the shorter protein consists of 160 amino acids
(pVHL18). Both proteins are functionally active and they
share the same mechanism of tumor suppressor activity
[6-8]. The VHL proteins form a multimeric complex with
Elongin B, Elongin C, Cul2 and Rbx1. This complex is
involved in ubiquitin-dependent proteolysis of large cel-
lular proteins via controlled degradation of α-subunits of
the heterodimeric transcription factor hypoxia inducible
factor (HIF) [9,10]. In addition, complexes containing
pVHL, Elongin B, Elongin C, Cul2 and Rbx1 target pro-
teins are involved in cell-cycle regulation for degradation,
suggesting that pVHL has a possible role in cell-cycle exit
[11]. In 1999, Stebbins and co-workers presented the
three-dimensional protein structure of the VHL-ElonginC-
ElonginB complex. They identified two functionally active
sites; the ElonginC binding site in the α-helical domain
involving residues between amino acids 157 and 170, and
the HIF binding site in the β-sheet domain from residue
91 to 113 [8].
The majority of VHL patients have deletions, insertions, or
mutations downstream of the second translational initia-
tion site located at codon 54 of the VHL gene. Interest-
ingly, missense mutations encoding residues of the
protein binding sites have been associated with VHL type
2, whereas VHL type 1 is caused either by missense or non-
sense mutations affecting the hydrophobic core, or by par-
tial gene deletions which result in a complete defect of
protein function. It has been also demonstrated that some
mutant pVHL, which are associated with the type 2C phe-
notype, may impair fibronectin matrix assembly while
they retain the ability to down regulate HIF [12].
Because mutations affecting the first 53 codons of the VHL
gene have no effect on the structure of the shorter VHL
protein, it seemed particularly interesting to clarify
whether these mutations could exert a pathogenic effect.
In one study the Pro25Leu variant has been associated
with a sporadic pheochromocytoma [13]. but other stud-
ies involving a limited number of cases failed to confirm
the pathogenic role of this variant [14,15]. In this paper
we report a large Hungarian VHL type 2 family with a dis-
ease-causing AGT80AAT (Ser80Ile) c.239G>A, p.Ser80Ile
mutation and a concurrent CCT25CTT (Pro25Leu)
c.74C>T, p.Pro25Leu variant (identification number:
rs35460768 (dbSNP127) of the VHL gene. We show that
in family members the Ser80Ile mutation, but not the
Pro25Leu variant co-segregated with the disease. In order
to confirm the pathogenicity of the Ser80Ile mutation and
to test whether the Pro25Leu variant might be neutral, an
evolutionary multiple sequence alignment analysis (MSA)
combined with a Align GVGD was.performed. Three-
dimensional modeling of the Ile80-mutant protein is also
presented.
Patients and methods
Patients and data collection
A large Hungarian VHL type 2 family spanning five gener-
ations and involving 32 members (Fig 1) was evaluated at
the 2nd Department of Medicine, Faculty of Medicine,
Semmelweis University in Budapest, Hungary. Initial
screening included medical history, physical examination,
abdominal ultrasonography, abdominal and brain com-
puted tomography (CT) or magnetic resonance imaging
(MRI), ophthalmologic examination, routine biochemi-
cal testing and 24-h urinary catecholamine metabolite
determinations.
Screening for VHL gene mutations
Written informed consent was obtained from all family
members who participated in the study. Genomic DNA
was extracted from peripheral blood leukocytes using
DNA isolation kit for mammalian blood samples (Boe-
hringer Mannheim Corporation, Indianapolis, IN). Muta-
tion analysis of the VHL gene was performed as previously
described [16].
Evolutionary alignment analysis of the VHL protein
Multiple sequence alignment (MSA) of protein sequences
was performed using 3D-coffee, a freely available web-
based tool for aligning multiple sequences [17]. A total of
eight sequences: Mus musculus (ENSMUSG0000003393
3), Rattus norvegicus (ENSRNOG00000010258), Canis
familiaris (ENSCAFG00000005149), Homo sapiens (EN
ST00000256474), Gallus gallus (ENSGALG0000000136
78), and evolutionary more distant species including Dro-
sophila melanogaster (CG13221_CG13221-RA), Xeno-
pus tropicalis (ENSXET00000001448) and Takifugu
rubripes (SINFRUG00000121189) were analysed.BMC Medical Genetics 2008, 9:29 http://www.biomedcentral.com/1471-2350/9/29
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One popular method for measuring biochemical dis-
tances between pairs of amino acids is the Grantham Dif-
ference (18), which takes into account the composition,
polarity and volume of mutant and wild-type amino
acids. In this study, we have constructed a VHL protein
MSA and combined a conservation score (GV) with a
measure of biochemical difference between wild-type and
mutant residues with respect to the alignment (GD). This
extension of the Grantham Difference, called Align
GVGD, has previously been successfully applied to BRCA1
and TP53 genes (19, 20). Align GVGD is freely available
online (21).
Three-dimensional structure modeling of the VHL protein
The coordinates of the pVHL were obtained from
1vcb_a.pdb structure file [8]. The three-dimensional
image was generated with Swiss-PdbViewer in combina-
tion with POV-Ray [22].
Results
Genotype-phenotype associations
The index patient was operated for pheochromocytoma
and renal cell carcinoma diagnosed at the age of 34 yr and
40 yr, respectively. She also developed a brain heman-
gioblastoma at the age of 42 yr. Genetic screening indi-
cated that she had a heterozygous AGT80AAT (Ser80Ile)
c.239G>A, p.Ser80Ile mutation of the VHL gene. The 70-
yr-old mother of the index patient proved to be not only
a gene carrier for the Ser80Ile mutation, but she also had
the CCT25CTT (Pro25Leu) c.74C>T, p.Pro25Leu variant
(identification number: rs35460768 (dbSNP127)), both
in heterozygous forms. However, the mother showed no
clinical, biochemical or radiological evidence of VHL-
associated tumors. The absence of the Pro25Leu variant in
the index patient indicated, that the Ser80Ile mutation
and the Pro25Leu variant in the mother were present in
separate alleles.
In addition to the index patient and her mother, the
Ser80Ile mutation was detected in other 5 members of the
Pedigree of a Hungarian kindred with von Hippel-Lindau disease Figure 1
Pedigree of a Hungarian kindred with von Hippel-Lindau disease.BMC Medical Genetics 2008, 9:29 http://www.biomedcentral.com/1471-2350/9/29
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family (III/7, III/8, IV/13, IV/14 and IV/16) (Fig 1), of
which all but one member (III/7, III/8, IV/13 and IV/14)
had clinical manifestations of the disease.
Importantly, pheochromocytomas were identified in fam-
ily members III/8 and IV/14, of whom, in patient IV/14
this was the first sign of the disease manifested at the age
of 10 years and involved both adrenals. Other typical
manifestations included brain hemangioblastomas in
family members: III/7, III/8 and IV/13, retina hemangiob-
lastomas in family members III/7, III/8, IV/13 and IV/14,
and renal cysts in family member IV/13. In addition, fam-
ily history revealed that one sister of the mother of the
index patient (II/5) died due to bilateral renal cell carcino-
mas. Another sister of the mother of the index patient
(II.4) died because of a metastatic pancreatic tumor with-
out histological confirmation and, therefore, this family
member was not considered as having VHL. The age, clin-
ical manifestations, and the age at diagnosis of VHL-asso-
ciated lesions in carriers of the Ser80Ile mutation and in
those with clinically proven VHL-associated tumors are
summarized in Table 1.
In addition to the mother of the index patient, the
Pro25Leu variant was detected on another family member
(III/6) (Fig 1), who was clinically healthy.
The prevalence of the Pro25Leu variant was tested in 16
members of other 8 VHL families and in 39 patients with
sporadic pheochromocytomas, but none of the patients
had this variant.
Evolutionary alignment analysis of the VHL gene
As shown in Fig. 2., the Ser at amino acid position 80 rep-
resents a highly conserved amino acid residue among dif-
ferent species, including rat, mouse, dog, chicken and an
evolutionary more distant species, Xenopus tropicalis. By
contrast, the Pro at amino acid position 25 failed to show
a conserved pattern. Using Align-GVGD criteria both var-
iants were predicted as neutral fulfilling the criteria 0<GV
≤ 61,3 and GD>0 (the calculated GV and GD scores for
Pro25Leu polymorphism were 218.82 and 4.86 and for
Ser80Ile 219.56 and 3.24, respectively).
Effect of change of Ser80 to Ile80 on protein structure
The three-dimensional model of the pVHL is available
from residue Met54, which allowed us to analyse func-
tional consequences of the Ser80Ile mutation using a
three-dimensional computational modeling. The CPK
diagram in Fig. 3 illustrates both the wild-type Ser80 and
the mutant Ile80 proteins. The Ser80 residue makes tight
junctions with Pro103 and Ile151 by hydrogen-bonds
between the amino group of Ser80 and the carboxyl oxy-
gen of Pro103 and Ile151. The Ser80 residue is located on
the same side where ElonginC binds, and residues Pro81
and Arg82 are involved in direct binding. The Asn78 resi-
due from the β-domain, together with hydrophobic core
residues (Pro86, Phe76, Phe119, Trp117 and Val130)
have important roles for structural integrity of the β-sand-
wich [8]. A change of Ser to Ile at position 80 disturbs this
integrity of the β-sandwich due to a change in the orienta-
tion of the Arg82 residue, which disturbs its linker role
and, consequently, the hydrogen bond between Arg82
and Leu153 disappears. It has been already demonstrated
that the Arg82 residue plays a central role in structural
integrity of the pVHL, as it makes significant hydrogen-
bond contacts with Leu153, Val155, Lys159 and Arg161
and, through these contacts; it is involved in interactions
between pVHL and ElonginC [8].
Discussion
In this paper we describe a large Hungarian VHL type 2
family consisting of 32 members, in whom a disease-caus-
ing AGT80AAT (Ser80Ile) c.239G>A, p.Ser80Ile mutation
Table 1: Clinical manifestations of VHL disease in carriers of the Ser80Ile mutation and/or the Pro25Leu variant and in those with 
clinically proven VHL-associated tumors
Family member 
(age, years)
Renal cell 
carcinoma (age 
at presentation, 
years)
Brain heman-
gioblastoma 
(age at 
presentation, 
years)
Pheochromo-
cytoma (age at 
presentation, 
years)
Retina heman-
gioblastoma 
(age at 
presentation, 
years)
Other clinical 
manifestations
Result of 
genetic 
screening
I I / 1  ( 7 0 ) ----- P r o 2 5 L e u  S e r 8 0 I l e
I I I / 6  ( 4 4 ) ----- P r o 2 5 L e u
II/5 (63) + bilateral (45) - - - ND
III/1* (42) + bilateral (40) + (42) + (34) - - Ser80Ile
III/7 (47) - + (37) - + (18) - Ser80Ile
III/8 (39) - + (38) + (39) + (29) - Ser80Ile
IV/13 (27) - + (22) - + (23) renal cysts (20) Ser80Ile
IV/14 (26) - - + bilateral (10) + (26) - Ser80Ile
I V / 1 6  ( 1 6 ) ----- S e r 8 0 I l e
*, index patient; -, present; +, absent; ND, not determined (DNA for genetic testing was not available)BMC Medical Genetics 2008, 9:29 http://www.biomedcentral.com/1471-2350/9/29
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and a concurrent CCT25CTT (Pro25Leu) c.74C>T,
p.Pro25Leu variant were identified. Screening of family
members indicated that 7 family members had the
Ser80Ile mutation and 2 members had the Pro25Leu var-
iant, and that the two genetic alterations were transmitted
in separate alleles. More importantly, we showed that the
Ser80Ile mutation, but not the Pro25Leu variant co-segre-
gated with the VHL type 2 phenotype and that the
Pro25Leu variant never occurred in family members who
had manifestations of the disease. However, one family
member who had both genetic alterations and one mem-
ber with the Ser80Ile mutation without the Pro25Leu var-
iant showed no manifestations of the disease, suggesting
that this variant is not pathogenic for VHL.
In order to predict the pathological role of the Pro25Leu
and Ser80Ile variants, first we constructed a multiple
sequence alignment using evolutionary distant species. It
has been shown previously that the addition of more dis-
tantly related sequences is essential for a more accurate
prediction (20). However, in our case this approach
revealed that both variants might be neutral, which is in
contrast with earlier clinical findings suggesting the dis-
ease causing role of the Ser80Ile but not of the Pro25Leu.
The Ser80Ile has been previously reported only in one
VHL patient without clear cell renal carcinoma [23], but
several other missense mutations at codon 80 have been
described. The Ser80Gly mutation has been detected in a
12-yr-old patient with bilateral pheochromocytomas and
multiple congenital malformations [24] and in a patient
with pheochromocytoma [25]. The Ser80Asn mutation
was identified in a Slovakian family with VHL type 1 phe-
notype including pancreatic islet tumor in one affected
individual [26]. In addition, the pathogenic role of
Ser80Arg [27,28] and Ser80Asn mutations has been also
documented in VHL patients [25]. Our study shows for
the first time that the Ser80Ile mutation is associated with
bilateral pheochromocytoma presented as a first manifes-
tation of the disease, which points out that VHL patients
harboring this mutation require careful screening for phe-
ochromocytoma.
The association between various missense mutations at
codon 80 of the VHL gene and VHL disease in previous
studies and ours is not unexpected, since our evolutionary
alignment analysis showed that in this position the Ser is
a highly conserved amino acid residue among different
species. Moreover, computational protein modeling of a
change of Ser to Ile at position 80 indicated potentially
important consequences on three-dimensional structure
of the pVHL. Ser80 is a polar amino acid located in the
hydrophobic core of the β-domain close to the α-β inter-
face of pVHL and ElonginC interaction. According to our
protein modeling, the change of Ser to a larger and non-
Alignment analysis of the VHL protein from Mus musculus (ENSMUSG00000033933), Rattus norvegicus  (ENSRNOG00000010258), Canis familiaris (ENSCAFG00000005149), Homo sapiens (ENST00000256474), Gallus gallus  (ENSGALG000000013678), Drosophila melanogaster (CG13221_CG13221-RA), Xenopus tropicalis (ENSXET00000001448)  and Takifugu rubripes (SINFRUG00000121189) Figure 2
Alignment analysis of the VHL protein from Mus musculus (ENSMUSG00000033933), Rattus norvegicus 
(ENSRNOG00000010258), Canis familiaris (ENSCAFG00000005149), Homo sapiens (ENST00000256474), Gallus gallus 
(ENSGALG000000013678), Drosophila melanogaster (CG13221_CG13221-RA), Xenopus tropicalis (ENSXET00000001448) 
and Takifugu rubripes (SINFRUG00000121189).BMC Medical Genetics 2008, 9:29 http://www.biomedcentral.com/1471-2350/9/29
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polar Ile at amino acid position 80 results in a complex
rearrangement of the three-dimensional structure of the
protein binding interface, which disturbs HIF1α and
fibronectin binding [29]. Miller and co-workers have
already demonstrated that VHL gene mutations within L1
and L7 loops distrupt the dynamic coupling of the pVHL
and HIF-1α and that this may be an important mecha-
nism for the development of tumors [30]. Other studies
using three-dimensional modeling and a computer algo-
rithm FOLDEF provided a quantitative estimation of the
importance of the interactions contributing to the stabil-
ity of proteins and protein complexes [31]. In the case of
the Ser80Ile, the free energy difference between the wild
type and mutant proteins was 12.2 kcal/mol, which is
higher than the previously established cut-off value for the
development of clear-cell renal carcinoma or pheochro-
mocytoma [32].
Although mutations affecting the first 53 codons of the
VHL gene have no effect on the structure of the shorter
VHL protein, a few mutations at codons 25, 38, 46 and 52
have been considered to exert a pathogenic role. The
Pro25Leu and Ser38Pro have been identified in patients
with pheochromocytomas, whereas the Glu46Stop and
Glu52Lys have been associated with VHL disease [32,27].
However, Rothberg et al. reported a VHL patient with two
VHL gene mutations, Pro25Leu and Pro86Arg, in whom
the Pro86Arg was considered more likely to be pathogenic
than the Pro25Leu based on an allelic frequency of 0.5%
of the latter variant in anonymized DNA samples [14].
This Pro25Leu variant was detected in other healthy VHL
Three-dimensional computational modeling of the Ser80 and Ile80 residues using CPK diagram (upper part) and schematic rep- resentation of hydrogen-bonds between residues Gly104 and Asn78, between Arg79 and Ile151, between Ser80 and Ile151,  beween Ser80 and Pro103, between Ser80 and Leu153, and between Pro103 and Arg82 in wild type pVHL and the conse- quences of the Ser to Ile change at amino acid position 80 (lower part) Figure 3
Three-dimensional computational modeling of the Ser80 and Ile80 residues using CPK diagram (upper part) 
and schematic representation of hydrogen-bonds between residues Gly104 and Asn78, between Arg79 and 
Ile151, between Ser80 and Ile151, beween Ser80 and Pro103, between Ser80 and Leu153, and between Pro103 
and Arg82 in wild type pVHL and the consequences of the Ser to Ile change at amino acid position 80 (lower 
part). All figures were generated with Swiss-PdbViewer in combination with POV-Ray.BMC Medical Genetics 2008, 9:29 http://www.biomedcentral.com/1471-2350/9/29
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family members from Poland and North America [33,14].
In agreement with these observations, the Pro25Leu car-
rier in our family had no manifestations of the disease,
suggesting that this variant does not represent a disease-
causing mutation.
Conclusion
The Ser80Ile mutation of the vhl gene in a large Hungarian
kindred was found to be associated with VHL type 2 pre-
senting with both pheochromocytoma and renal cell can-
cer. Therefore, patients with this mutation require careful
surveillance, including search for pheochromocytoma.
The Pro25Leu variant in this family apeared to be neutral,
but its co-existence made genetic counseling difficult.
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